About Us

The first human antibody library platform
built-up in Korea reaching the globe

2021
03
  • - Entered into joint study and optional License Agreement for the development of new immunotherapies with
    Pierre Fabre Medicament
  • - Signed MOU for strategic collaboration for the development of next-generation ADC with AbTis
01
  • Passed KOSDAQ technology evaluation for listing,
    “A, A” level
2020
12
  • - IR52 Jang Young-Shil Award for Technology Innovation
    (Award from Ministry of Science and ICT)
  • - License Agreement granting exclusive rights of YBL-013, a T cell bi-specific engager based on ALiCE platform technology, in the territory of Greater China to
    3D Medicines Inc.
  • - Signed MOU for novel ADC co-development and research collaboration of drug combination with LegoChem Biosciences, Inc.
  • - License Agreement granting global sales rights (Korea excluded) of YBL-001, DLK-1 ADC co-developed with LegoChem Biosciences, Inc., to Pyxis Oncology, Inc.
09
  • Signed MOU for strategic collaboration for the development of universal cancer immunotherapy with Vaxcell-Bio Therapeutics, Co. Ltd
07
  • Agreed on non-exclusive license to use the sequence of novel antibody therapeutics of IO drugs with ViroCure
07
  • Collaboration agreement for R&D of antibody drug for prevention and therapeutics of COVID-19 with Genexine
06
  • Agreed on non-exclusive license to use the monoclonal antibody in field of IO targets with GI Innovation
2019
10
  • Collaboration agreement of bispecific antibody based on ALiCE platform with Pascal Biosciences
06
  • Collaboration development of novel IO bispecific antibody with Dualogics
2018
11
  • Quaternary investment of KRW 37 billion for the validation of novel bispecific antibody platform, ALiCE and development of IO clinical trials
2016
12
  • Tertiary investment of KRW 5 billion
06
  • ANRT and Y-Biologic merged into “Y-Biologics Inc.”
05
  • Agreed on collaborative research with HK inno.N (CJ Healthcare)
05
  • Secondary investment of KRW 10 billion for the discovery and development of novel IO antibody pipelines
2015
10
  • Primary investment of KRW 1 billion
2014
08
  • Agreed on 2nd collaborative R&D with Sanofi S.A.
2012
11
  • Agreed on collaborative R&D for novel antibody therapeutics targeting HCC with Sanofi S.A.
2010
03
  • Licensed out novel antibody therapeutics targeting autoimmune diseases with HanAll BioPharma Co.
2007
12
  • Founded as ANR Therapeutics